Life, changing.
More than 600,000 cancer patients worldwide have used our
Oncotype DX tests to personalize treatments and improve outcomes.
Our Mission
Genomic Health’s mission is to transform treatment decisions and outcomes in cancer by delivering clinically actionable diagnostics and services.
Oncotype IQ
Our portfolio of tests and services is aimed at delivering genomic intelligence that optimizes treatment decisions and outcomes throughout the cancer patient journey.
Our Pipeline
Developing liquid- and tissue-based genomic tests that address critical treatment questions throughout all stages of cancer.

Making An Impact

Genomic Health is leading in the precision medicine revolution to eliminate the "one-size-fits-all" approach to cancer treatment.
Predicting Cancer Outcomes
Oncotype DX leads industry as only test proven to predict chemotherapy benefit and with prospective clinical outcomes data in more than 50,000 breast cancer patients worldwide.
Oncotype DX - Outcomes Matter

As the only test proven to predict chemotherapy benefit, the Oncotype DX breast cancer test is considered standard of care for women with early-stage breast cancer.

Broadening Reimbursement for Patients Worldwide
Genomic Health is dedicated to securing reimbursement to ensure cancer patients around the world have access to our clinically actionable Oncotype DX tests. Outside the U.S., there are over 185 million lives covered and growing. The Oncotype DX prostate cancer test is now covered by Medicare in the U.S. for qualified patients, giving nearly 60,000 prostate cancer patients the opportunity to personalize their cancer treatment.
“I was determined to educate myself about all of my options, and thanks to Oncotype DX, I have not lost any sleep or been worried since I decided to go on active surveillance based on my very low GPS result.”

Dan W.